1Perry CM,Jarvis B. Peginterferon α 2a (40 kD): A review of its use in the management of chronic hepatitis C. Drugs ,2001,61:2263
2Lam NP, Neunann AU, Gretch DR, et al. Dose dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology, 1997,26: 226
3Kozlowski A, Charles SA, Harris MJ. Development of pegylated interferons for the treament of chronic hepatitis C. Biodrugs, 2001,15:419
4Zeuzen S,Feinman SV,Rasenack J,et al. Peginterferon α-2a in patients with chronic hepatitis C. N Engl J Med, 2000,343:1666
5Reddy KR. Controlled-release, pegylated, liposomal formulations:new mechanisms in the delivery of injectable drugs. Ann Pharmacother,2000,34:915
6Modi MW,Fulton JS,Buckmnann DK,et al. Clearance of pegylated (40kD) interferon a-2a is primarily hepatic. Hepatology,2000,32:371A
7McHutchison JG, Gordon SC, Schiff ER, et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med, 1998,339:1485
8Modi MW, Fried M, Reindollar RW, et al. The pharmacokinetic behavior of pegylated (40 kDa) interferon α-2a in chronic hepatitis C patients after multiple dosing. Hepatology,2000,32:394
9Heathcote EJ, Shiffman ML, Cooksley GE, et al. Peginterferon α2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med, 2000,343:1673
10Fried MW,Shiffman ML,Reddy KR, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med,2002,347: 975
